Butyrolactone I, ATP-competitive cyclin-dependent kinase (CDK) inhibitor (ab141520)

Overview

  • Product name

    Butyrolactone I, ATP-competitive cyclin-dependent kinase (CDK) inhibitor
  • Description

    Cell permeable, selective, ATP-competitive cyclin-dependent kinase (CDK) inhibitor
  • Biological description

    Cell permeable, selective, ATP-competitive CDK inhibitor. Inhibits CDC2, CDK2, and CDK5. Inhibits the cell cycle at G1/S and G2/M. Apoptotic and antitumor activity.
  • Purity

    > 97%
  • CAS Number

    87414-49-1
  • Chemical structure

    Chemical Structure

Properties

References

This product has been referenced in:

  • Ruffner H  et al. BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. Mol Cell Biol 19:4843-54 (1999). Read more (PubMed: 10373534) »
  • Kitagawa M  et al. A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression. Oncogene 9:2549-57 (1994). Read more (PubMed: 8058318) »
  • Kitagawa M  et al. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8:2425-32 (1993). Read more (PubMed: 8395680) »
  • Nishio K  et al. Antitumor effects of butyrolactone I, a selective cdc2 kinase inhibitor, on human lung cancer cell lines. Anticancer Res 16:3387-95 (0). Read more (PubMed: 9042196) »
  • Wada M  et al. An exogenous cdk inhibitor, butyrolactone-I, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer Res 18:2559-66 (0). Read more (PubMed: 9703910) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab141520.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up